TAK-003: development of a tetravalent dengue vaccine
Introduction Dengue incidence has increased over the past few decades. One tetravalent dengue vaccine based on a yellow fever backbone has been approved, but due to increased risk of severe disease in dengue-naïve recipients, its use is limited to individuals with prior dengue exposure.Areas covered...
Saved in:
| Main Authors: | Xavier Sáez-Llorens, Rodrigo DeAntonio, Jenny Guek Hong Low, Pope Kosalaraksa, Hansi Dean, Mayuri Sharma, Vianney Tricou, Shibadas Biswal |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2025.2490295 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Methodological Approach to Measuring the Impact of TAK-003 for the Prevention of Dengue in Dourados, Brazil: Optimizing Strategies for Public Health
by: Benedetta Ghezzi, et al.
Published: (2025-01-01) -
Dengue Vaccine Development and Deployment into Routine Immunization
by: Annelies Wilder-Smith, et al.
Published: (2025-04-01) -
Unveiling the complexity of vaccine hesitancy: A narrative review focusing on dengue vaccination
by: Rachata Charoenwisedsil, et al.
Published: (2025-12-01) -
The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review
by: Raksheeth Agarwal, et al.
Published: (2017-05-01) -
The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review
by: Raksheeth Agarwal, et al.
Published: (2017-05-01)